Featured Posters & Presentations
Lyfgenia
lovo-cel (bb1111) gene therapy for sickle cell disease: updated clinical results and investigations into two cases of anemia from Group C of the Phase 1/2 HGB-206 Study.
Authors: Walters MC.
Zynteglo
Long-term outcomes of 63 patients with transfusion-dependent β-thalassemia (TDT) followed up to 8 years post-treatment with betibeglogene autotemcel (beti-cel) gene therapy and exploratory analysis of predictors.
Authors: Walters MC.